Imaging in Therapy Response Assessment and Surveillance of Lung Cancer: Evidenced-based Review With Focus on the Utility of 18F-FDG PET/CT

Sara Sheikhbahaei; Franco Verde; Russell K. Hales; Steven P. Rowe; Lilja B. Solnes

doi:10.1016/j.cllc.2020.06.020

Imaging in Therapy Response Assessment and Surveillance of Lung Cancer: Evidenced-based Review With Focus on the Utility of ¹⁸F-FDG PET/CT

Sara Sheikhbahaei, Franco Verde, Russell K. Hales, Steven P. Rowe, Lilja B. Solnes

School of Medicine

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

This review covers the state-of-the-art imaging in therapy assessment and surveillance of lung cancer with focus on the utility of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT). We review different qualitative and quantitative response assessment criteria in lung cancer, common pitfalls and atypical patterns of response to immunotherapy, and imaging features of common immune-related adverse events. In addition, the currently recommended imaging workup in surveillance of asymptomatic patients with non–small-cell and small-cell lung cancer and future developments will be discussed.

Original language	English (US)
Pages (from-to)	485-497
Number of pages	13
Journal	Clinical lung cancer
Volume	21
Issue number	6
DOIs	https://doi.org/10.1016/j.cllc.2020.06.020
State	Published - Nov 2020

Keywords

F-FDG PET/CT
Non–small-cell lung cancer
Small-cell lung cancer
Surveillance
Therapy assessment

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.1016/j.cllc.2020.06.020

Cite this

@article{7485931963d841699387c421ae812269,

title = "Imaging in Therapy Response Assessment and Surveillance of Lung Cancer: Evidenced-based Review With Focus on the Utility of 18F-FDG PET/CT",

abstract = "This review covers the state-of-the-art imaging in therapy assessment and surveillance of lung cancer with focus on the utility of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). We review different qualitative and quantitative response assessment criteria in lung cancer, common pitfalls and atypical patterns of response to immunotherapy, and imaging features of common immune-related adverse events. In addition, the currently recommended imaging workup in surveillance of asymptomatic patients with non–small-cell and small-cell lung cancer and future developments will be discussed.",

keywords = "F-FDG PET/CT, Non–small-cell lung cancer, Small-cell lung cancer, Surveillance, Therapy assessment",

author = "Sara Sheikhbahaei and Franco Verde and Hales, {Russell K.} and Rowe, {Steven P.} and Solnes, {Lilja B.}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = nov,

doi = "10.1016/j.cllc.2020.06.020",

language = "English (US)",

volume = "21",

pages = "485--497",

journal = "Clinical lung cancer",

issn = "1525-7304",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Imaging in Therapy Response Assessment and Surveillance of Lung Cancer

T2 - Evidenced-based Review With Focus on the Utility of 18F-FDG PET/CT

AU - Sheikhbahaei, Sara

AU - Verde, Franco

AU - Hales, Russell K.

AU - Rowe, Steven P.

AU - Solnes, Lilja B.

PY - 2020/11

Y1 - 2020/11

N2 - This review covers the state-of-the-art imaging in therapy assessment and surveillance of lung cancer with focus on the utility of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). We review different qualitative and quantitative response assessment criteria in lung cancer, common pitfalls and atypical patterns of response to immunotherapy, and imaging features of common immune-related adverse events. In addition, the currently recommended imaging workup in surveillance of asymptomatic patients with non–small-cell and small-cell lung cancer and future developments will be discussed.

AB - This review covers the state-of-the-art imaging in therapy assessment and surveillance of lung cancer with focus on the utility of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). We review different qualitative and quantitative response assessment criteria in lung cancer, common pitfalls and atypical patterns of response to immunotherapy, and imaging features of common immune-related adverse events. In addition, the currently recommended imaging workup in surveillance of asymptomatic patients with non–small-cell and small-cell lung cancer and future developments will be discussed.

KW - F-FDG PET/CT

KW - Non–small-cell lung cancer

KW - Small-cell lung cancer

KW - Surveillance

KW - Therapy assessment

UR - http://www.scopus.com/inward/record.url?scp=85088789847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088789847&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2020.06.020

DO - 10.1016/j.cllc.2020.06.020

M3 - Review article

C2 - 32723523

AN - SCOPUS:85088789847

SN - 1525-7304

VL - 21

SP - 485

EP - 497

JO - Clinical lung cancer

JF - Clinical lung cancer

IS - 6

ER -